FDA Approves Pharmacyclics’ IMBRUVICA® (ibrutinib) for Adult Patients with Chronic Graft Versus Host Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy
FDA Approves Celgene’s IDHIFA® (enasidenib) for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
FDA Approves RITUXAN HYCELA™ (rituximab/hyaluronidase human)
AstraZeneca Access 360™ Provides Patient Access, Reimbursement Support, and Information about Affordability Programs for AstraZeneca’s Medicines
Follow RMOS on Twitter
What's New @ RMOS:
RMOS Sponsors Colorado Cancer Coalition Symposium. Register Today!
Did You Miss Our Symposium on Immune-Related Adverse Events (irAEs)? Get Access to the Recording!
RMOS Submits Letter Regarding Medicare Part B to Department of Health and Human Services
AstraZeneca's TAGRISSO® (osimertinib) Receives FDA Full Approval
View the RMOS 2016 Year in Review!
| ACCC Resources
| ASCO Resources
| ASCO Connection |
© Oncology State Society Network. All rights reserved.